One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption

被引:63
|
作者
Varela, Aurore [1 ]
Chouinard, Luc [1 ]
Lesage, Elisabeth [1 ]
Smith, Susan Y. [1 ]
Hattersley, Gary [2 ]
机构
[1] Charles River Labs, Montreal, PQ, Canada
[2] Radius Hlth Inc, Waltham, MA USA
关键词
ABALOPARATIDE; PTHrP; ANABOLIC AGENTS; BONE FORMATION; OSTEOPOROSIS; HORMONE-RELATED PEPTIDE; INTERMITTENT-PARATHYROID-HORMONE; RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY; MINERAL DENSITY; OSTEOBLAST LINEAGE; ANABOLIC ACTIVITY; DEFICIENT MICE; CORTICAL BONE;
D O I
10.1002/jbmr.3003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Abaloparatide is a novel 34-amino acid peptide selected to be a potent and selective activator of the parathyroid hormone receptor (PTH1R) signaling pathway with 41% homology to PTH(1-34) and 76% homology to PTHrP(1-34). A 12-month treatment study was conducted in osteopenic ovariectomized (OVX) rats to characterize the mechanisms by which abaloparatide increases bone mass. Sprague-Dawley (SD) rats were subjected to OVX or sham surgery at age 6 months and left untreated for 3 months to allow OVX-induced bone loss. Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n=18) or abaloparatide at 1, 5, or 25g/kg/d (n=18/dose level) for 12 months. Sham controls (n=18) received vehicle daily. Bone densitometry and biochemical markers of bone formation and resorption were assessed longitudinally, and L-3 vertebra and tibia were collected at necropsy for histomorphometry. Abaloparatide increased biochemical bone formation markers without increasing bone resorption markers or causing hypercalcemia. Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces. Abaloparatide induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Abaloparatide stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) remained stable in OVX-Vehicle controls while increasing 25% after 12 months of abaloparatide (25g/kg). Histomorphometry and biomarker data suggest that gains in cortical and trabecular bone mass were attributable to selective anabolic effects of abaloparatide, without evidence for stimulated bone resorption. (c) 2016 American Society for Bone and Mineral Research.
引用
收藏
页码:24 / 33
页数:10
相关论文
共 50 条
  • [1] One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats
    Varela, Aurore
    Chouinard, Luc
    Lesage, Elisabeth
    Guldberg, Robert
    Smith, Susan Y.
    Kostenuik, Paul J.
    Hattersley, Gary
    BONE, 2017, 95 : 143 - 150
  • [2] Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
    Doyle, N.
    Varela, A.
    Haile, S.
    Guldberg, R.
    Kostenuik, P. J.
    Ominsky, M. S.
    Smith, S. Y.
    Hattersley, G.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (03) : 685 - 697
  • [3] Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
    N. Doyle
    A. Varela
    S. Haile
    R. Guldberg
    P. J. Kostenuik
    M. S. Ominsky
    S. Y. Smith
    G. Hattersley
    Osteoporosis International, 2018, 29 : 685 - 697
  • [4] Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption
    Chandler, Heidi
    Lanske, Beate
    Varela, Aurore
    Guillot, Martin
    Boyer, Marilyne
    Brown, Jeffrey
    Pierce, Allen
    Ominsky, Michael
    Mitlak, Bruce
    Baron, Roland
    Kostenuik, Paul
    Hattersley, Gary
    BONE, 2019, 120 : 148 - 155
  • [5] Abaloparatide promotes bone repair of vertebral defects in ovariectomized rats by increasing bone formation
    Makino, Akito
    Hasegawa, Tomoka
    Yamamoto, Tomomaya
    Takagi, Hideko
    Takahashi, Yoshimasa
    Miyakoshi, Naohisa
    Amizuka, Norio
    BONE, 2024, 182
  • [6] Abaloparatide Improves Bone Mass and Microarchitecture, without increasing Bone Resorption, in Adult Rats Subjected to Hindlimb Unloading
    Teguh, Dian A.
    Craven, Amanda E.
    Nustad, Jordan L.
    Brooks, Daniel J.
    Arlt, Heike
    Lanske, Beate
    Bouxsein, Mary L.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 63 - 64
  • [7] Abaloparatide, a Selective PTH1 Receptor Agonist, Reversed Bone Loss and Improved Trabecular Architecture in Orchiectomized Rats.
    Chandler, Heidi
    Mullarkey, Tara
    Stewart, Rachel
    Hattersley, Gary
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S275 - S275
  • [8] Abaloparatide Increases Bone Formation and Mass in Orchiectomized Male Rats with No Effect on Bone Resorption
    Chandler, Heidi
    Brooks, Daniel
    Nagano, Kenichi
    Hu, Dorothy
    Bouxsein, Mary
    Baron, Roland
    Hattersley, Gary
    Lanske, Beate
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 407 - 407
  • [9] Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading
    Teguh, Dian A.
    Nustad, Jordan L.
    Craven, Amanda E.
    Brooks, Daniel J.
    Arlt, Heike
    Hu, Dorothy
    Baron, Roland
    Lanske, Beate
    Bouxsein, Mary L.
    BONE, 2021, 144
  • [10] Treatment with an anti-sclerostin antibody increased bone mass by stimulating bone formation without increasing bone resorption in aged male rats
    Li, X.
    Warmington, K. S.
    Niu, Q.
    Grisanti, M.
    Tan, H.
    Dwyer, D.
    Stolina, M.
    Ominsky, M. S.
    Simonet, W. S.
    Kostenuik, P. J.
    Paszty, C.
    Ke, H. Z.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S36 - S36